The “Silo” Problem Data fragmentation is the number one blocker for AI adoption in Pharma. Even industry giants like Novartis have publicly noted the extreme difficulty of cleaning and linking heterogeneous data across a global organization. Valuable data sits trapped in different formats (structured SQL vs. unstructured pathology images), different legacy applications (old ELNs vs. […]
The Value of “Old” Drugs Discovering a new chemical entity (NCE) is risky 90% fail. Drug Repurposing (finding new uses for existing drugs) is the strategic shortcut. These drugs have already passed toxicity screens; their safety profiles are known. A famous example of this is Baricitinib. Originally a rheumatoid arthritis drug, it was identified by […]
The Cost Barrier is Gone For decades, high-fidelity molecular modeling was a luxury reserved for the “Big Pharma” elite. Developing a new drug costs nearly $2 billion, and a significant portion of that budget goes into massive High-Performance Computing (HPC) clusters required to run complex simulations. Small biotechs and startups were forced to rely on […]
What is AI Data Management in Life Sciences? We are living in the “Decade of Data.” The biomedical domain has seen an explosion of information, driven by the plummeting cost of Next Generation Sequencing (NGS), the digitization of health records, and the rise of wearable sensors. However, for most Pharma organizations, this data is a […]
Introduction: The Promise vs. The Reality of Pharma AI The pharmaceutical industry is currently navigating a paradoxical “drug drought.” Over the last decade, R&D investment has skyrocketed, yet the return on investment (ROI) for the top pharmaceutical companies has plummeted dropping from roughly 10% in 2010 to under 2% recently. The industry is desperate for […]
Key Takeaways Structure-to-affinity modeling is the missing bridge between protein structure prediction and real-world drug discovery outcomes. OpenFold3 enables reproducible, transparent protein structure generation without reliance on closed vendor APIs. Open-source affinity pipelines unlock explainability, auditability, and scientific control that black-box AI platforms cannot provide. AI-ready data platforms are required to operationalize these models at […]
